Massimo Saini - Captaim
CTC Apheresis for Personalized Targeted & Immune Therapy
The development of anti-cancer mRNA vaccines has become reality and may revolutionize precision oncology by providing a new generation of highly personalized immunotherapies, tailored to target specific neo-antigens in individual cancer patients.
The CAPTAIM technology is a next-generation liquid biopsy tool, based on blood analysis via the combined use of cytapheresis and microfluidics, geared to provide high-quality predictive markers for personalized immunotherapy. Our technology can be greatly advantageous to patients with inoperable cancers, whose treatment decisions are hampered by the inaccessibility of their tumor lesions. We envision CAPTAIM to overcome the invasiveness, as well as spatial and temporal sampling biases of standard biopsies, providing a new exceptional tool in the fight against cancer.
Full team: Massimo Saini (Pioneer fellow), Alexander Ring, Nicola Aceto and Andreas Wicki (Co-inventors)